Cargando…

Glycyrrhizic Acid Inhibits High-Mobility Group Box-1 and Homocysteine-Induced Vascular Dysfunction

Hyperhomocysteinemia (HHcy) worsens cardiovascular outcomes by impairing vascular function and promoting chronic inflammation via release of danger-associated molecular patterns, such as high-mobility group box-1 (HMGB-1). Elevated levels of HMGB-1 have recently been reported in patients with HHcy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Gadanec, Laura Kate, Andersson, Ulf, Apostolopoulos, Vasso, Zulli, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383373/ https://www.ncbi.nlm.nih.gov/pubmed/37513606 http://dx.doi.org/10.3390/nu15143186

Ejemplares similares

Combination of Taurine and Black Pepper Extract as a Treatment for Cardiovascular and Coronary Artery Diseases
por: Swiderski, Jordan, et al.
Publicado: (2023)

Could DIZE be the answer to COVID-19?
por: Qaradakhi, Tawar, et al.
Publicado: (2020)

Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?
por: Gadanec, Laura Kate, et al.
Publicado: (2021)

The Anti-Inflammatory Effect of Taurine on Cardiovascular Disease
por: Qaradakhi, Tawar, et al.
Publicado: (2020)

Dual targeting of toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment
por: Kate Gadanec, Laura, et al.
Publicado: (2021)

Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations
por: McSweeney, Kristen Renee, et al.
Publicado: (2021)

Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019
por: Swiderski, Jordan, et al.
Publicado: (2023)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy
por: Ridgway, Harry, et al.
Publicado: (2022)

Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2
por: Matsoukas, John M., et al.
Publicado: (2022)

Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2
por: Ridgway, Harry, et al.
Publicado: (2022)

Glycyrrhizic acid nanoparticles inhibit LPS-induced inflammatory mediators in 264.7 mouse macrophages compared with unprocessed glycyrrhizic acid
por: Wang, Wei, et al.
Publicado: (2013)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes
por: Asseri, Saad Mohamed, et al.
Publicado: (2022)

High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease
por: Pisetsky, David S, et al.
Publicado: (2008)

High Mobility Group Box 1 Mediates TMAO-Induced Endothelial Dysfunction
por: Singh, Gurinder Bir, et al.
Publicado: (2019)

Extraction of Glycyrrhizic Acid and Glabridin from Licorice
por: Tian, Minglei, et al.
Publicado: (2008)

Glycyrrhizic acid derivatives as Dengue virus inhibitors
por: Baltina, Lidia A., et al.
Publicado: (2019)

Advances in the roles of glycyrrhizic acid in cancer therapy
por: Zhang, Yuqian, et al.
Publicado: (2023)

Selective and competitive inhibition of kynurenine aminotransferase 2 by glycyrrhizic acid and its analogues
por: Yoshida, Yukihiro, et al.
Publicado: (2019)

Glycyrrhizic Acid in the Treatment of Liver Diseases: Literature Review
por: Li, Jian-yuan, et al.
Publicado: (2014)

Antagonism of Cerebral High Mobility Group Box 1 Ameliorates Dendritic Cell Dysfunction in Sepsis
por: Ren, Chao, et al.
Publicado: (2021)

Homocysteine causes vascular endothelial dysfunction by disrupting endoplasmic reticulum redox homeostasis
por: Wu, Xun, et al.
Publicado: (2018)

Homocysteine Disulphides and Vascular Disease
por: Iuliano, Mauro, et al.
Publicado: (2009)

High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
por: Wähämaa, Heidi, et al.
Publicado: (2011)

Glycyrrhizic Acid Inhibits Proliferation of Gastric Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis
por: Wang, Hao, et al.
Publicado: (2020)

Glycyrrhizic Acid Prevents Paclitaxel-Induced Neuropathy via Inhibition of OATP-Mediated Neuronal Uptake
por: Klein, Ines, et al.
Publicado: (2023)

High-mobility group box-1 induces vascular remodelling processes via c-Jun activation
por: Zabini, Diana, et al.
Publicado: (2015)

Glycyrrhizic acid alleviates bleomycin-induced pulmonary fibrosis in rats
por: Gao, Lili, et al.
Publicado: (2015)

The Effects of Sweet Foods on the Pharmacokinetics of Glycyrrhizic Acid by icELISA
por: Jiang, Bingqian, et al.
Publicado: (2017)

Effect of Glycyrrhizic Acid on Scopolamine-Induced Cognitive Impairment in Mice
por: Ban, Ju Yeon, et al.
Publicado: (2020)

Dipotassium Glycyrrhizate Inhibits HMGB1-Dependent Inflammation and Ameliorates Colitis in Mice
por: Vitali, Roberta, et al.
Publicado: (2013)

Vaccine Delivery Methods into the Future
por: Apostolopoulos, Vasso
Publicado: (2016)

Cancer Vaccines: Research and Applications
por: Apostolopoulos, Vasso
Publicado: (2019)

Targeting High Mobility Group Box 1 in Subarachnoid Hemorrhage: A Systematic Review
por: Muhammad, Sajjad, et al.
Publicado: (2020)

Synthesis, Antiviral, and Antibacterial Activity of the Glycyrrhizic Acid and Glycyrrhetinic Acid Derivatives
por: Mohammed, E. A. H., et al.
Publicado: (2022)

High-mobility group box 1: role in ARDS
por: Ishizaka, A, et al.
Publicado: (2005)

High‐Mobility Group Box‐1 and Liver Disease
por: Gaskell, Harriet, et al.
Publicado: (2018)

High mobility group box 1 in diabetic nephropathy
por: Shi, Haitao, et al.
Publicado: (2017)

High Mobility Group Box 1 in Human Cancer
por: Rapoport, Bernardo L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3pbljghgbs6mvr6otkionqtf1t